Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
NCT03948529 · University Hospital, Lille · PHASE2 · terminated · last registry update 2025-09-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “inclusions difficulties.” | – | Registry record, University Hospital, Lille |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-16Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Eltrombopag (NCT03206086)
- 2026-08-26Phase 3 first posted: Swedish Orphan Biovitrum, Avatrombopag 20 mg Oral Tablet (NCT07786922)
- 2026-08-10Results posted on the registry: Novartis Pharmaceuticals, Eltrombopag + hATG (NCT03025698)
- 2026-07-13Phase 3 first posted: Amgen, Romiplostim + Predniso(lo)ne (NCT07700238)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Romiplostim N01 (NCT07532408)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Cyclosporine (CsA) + Thrombopoietin Receptor Agonist (NCT07523009)
- 2026-02-11Results posted on the registry: Amgen, Romiplostim (NCT03362177)
- 2026-01-15Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Romiplostim N01 + Cyclosporine A (CsA) (NCT07345000)
- 2026-01-09Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Eltrombopag + Cyclosporine (NCT04304820)
- 2025-12-16Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Hetrombopag Olamine + Hetrombopag Olamine; Hetrombopag Olamine Placebo (NCT07286032)
- 2025-12-12Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Avatrombopag+All trans retinoic acid + Avatrombopag (NCT07278908)
- 2025-07-29Results posted on the registry: Baylor College of Medicine, Eltrombopag + Steroids (NCT03939637)
- 2025-07-17Results posted on the registry: Novartis Pharmaceuticals, eltrombopag + rabbit anti-thymocyte globulin (r-ATG) (NCT04328727)
- 2025-07-04Phase 3 first posted: Ostfold Hospital Trust, Avatrombopag + Rituximab (Arm B) (NCT07051915)
- 2025-06-03Phase 3 first posted: Peking Union Medical College Hospital, EPAG-pfos (NCT07001397)
- 2025-05-28Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Romiplostim (NCT04671901)
- 2025-03-17Results posted on the registry: Novartis Pharmaceuticals, Eltrombopag + Dexamethasone (NCT04346654)
- 2025-02-11Results posted on the registry: Sobi, Inc., Avatrombopag Oral Tablet (NCT05369208)
- 2025-02-03Results posted on the registry: Novartis Pharmaceuticals, Eltrombopag (NCT03988608)
- 2025-01-17Results posted on the registry: Sobi, Inc., Avatrombopag + Placebo (NCT04516967)
- 2025-01-16Results posted on the registry: Sobi, Inc., Avatrombopag Oral Tablet (NCT04638829)
- 2025-01-15Also stopped (withdrawn): University of Rochester, Avatrombopag (NCT04931849)
- 2025-01-06Phase 3 first posted: The First Affiliated Hospital with Nanjing Medical University, Romiplostim N01 + Recombinant Human Interleukin-11 (rhIL-11) (NCT06759636)
- 2024-12-27Results posted on the registry: Memorial Sloan Kettering Cancer Center, romiplostim (NCT02052882)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision